Scott Kogan
Overview
Explore the profile of Scott Kogan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bidkar A, Peter R, Wadhwa A, Bobba K, Bidlingmaier S, Meher N, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39945595
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and a poor prognosis. Recently, PSMA-targeted alpha particle therapy agents using Actinium-225 (225Ac) have shown promising results for prostate cancer...
2.
de Smith A, Liu T, Xu K, Pardeshi A, Myint S, Kang A, et al.
Res Sq
. 2024 Jul;
PMID: 38946984
Acute lymphoblastic leukemia (ALL) is the most common cancer in children, yet few environmental risk factors have been identified. We previously found an association between early-life tobacco smoke exposure and...
3.
Thomas A, Fang M, Kogan S, Hubbard C, Friedman P, Gong L, et al.
JACC Adv
. 2023 Nov;
1(2).
PMID: 37961076
Background: Direct-acting oral anticoagulants are first-line agents for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF), but data are limited for the oldest patients, and with reduced dosing....
4.
Carnevale J, Shifrut E, Kale N, Nyberg W, Blaeschke F, Chen Y, et al.
Nature
. 2022 Aug;
609(7925):174-182.
PMID: 36002574
The efficacy of adoptive T cell therapies for cancer treatment can be limited by suppressive signals from both extrinsic factors and intrinsic inhibitory checkpoints. Targeted gene editing has the potential...
5.
Qi Z, Wen K, Ki A, Prakash S, Kogan S, Yu J
Cytogenet Genome Res
. 2022 Jun;
162(3):119-123.
PMID: 35675801
Interstitial deletion in the long arm of chromosome 9 [del(9q)] is a fairly common cytogenetic finding associated with acute myeloid leukemia (AML), seen in approximately 2-5% of AML patients. However,...
6.
Feng Q, de Smith A, Vergara-Lluri M, Muskens I, McKean-Cowdin R, Kogan S, et al.
Am J Epidemiol
. 2020 Oct;
190(4):519-527.
PMID: 33034340
Incidence trends in acute lymphoblastic leukemia (ALL) demonstrate disparities by race and ethnicity. We used data from the Surveillance, Epidemiology, and End Results Registry to evaluate patterns in ALL incidence...
7.
Morimoto L, Kwan M, Deosaransingh K, Munneke J, Kang A, Quesenberry C, et al.
Am J Epidemiol
. 2020 Apr;
189(10):1076-1085.
PMID: 32322901
Surrogate measures of infectious exposures have been consistently associated with lower childhood acute lymphoblastic leukemia (ALL) risk. However, recent reports have suggested that physician-diagnosed early-life infections increase ALL risk, thereby...
8.
Esnault C, Rahme R, Rice K, Berthier C, Gaillard C, Quentin S, et al.
Blood
. 2019 Jan;
133(13):1495-1506.
PMID: 30674471
Acute promyelocytic leukemia (APL) is often associated with activating FLT3 signaling mutations. These are highly related to hyperleukocytosis, a major adverse risk factor with chemotherapy-based regimens. APL is a model...
9.
Lehmann-Che J, Bally C, Letouze E, Berthier C, Yuan H, Jollivet F, et al.
Nat Commun
. 2018 May;
9(1):2047.
PMID: 29795382
Retinoic acid (RA) and arsenic target the t(15;17)(q24;q21) PML/RARA driver of acute promyelocytic leukemia (APL), their combination now curing over 95% patients. We report exome sequencing of 64 matched samples...
10.
Foley N, Van Ziffle J, Yu J, Qi Z, Grenert J, Yeh I, et al.
Cancer Genet
. 2017 Oct;
216-217:74-78.
PMID: 29025598
In acute myeloid leukemia (AML), a translocation between chromosomes 8q22 and 21q22 leads to the RUNX1-RUNXT1 fusion gene which, in the absence of a concomitant KIT mutation, generally portends a...